Clinical trials: Elderly Infection
RSV Infection, Respiratory Syncytial Virus Infections
RESCEU Study, Defining the Burden of Disease of RSV in Older Adults
The REspiratory Syncytial virus Consortium in EUrope (RESCEU) is an Innovative Medicine Initiative (IMI) funded by the EU under the H2020 framework to define and understand the burden of disease caused by human respiratory…
- Conditions
- RSV Infection, Respiratory Syncytial Virus Infections, Bronchiolitis
- Trial name
- NCT03621930
- Where
- 3 sites in Belgium, Netherlands and 1 more
- Volunteers
- 1,040 people, healthy volunteers welcome
- Sponsor
- UMC Utrecht
Pneumococcal Infectious Disease
Clinical Trial of PCV24 in Children Aged 2-17 Years
A Phase Ia clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2-17 years.
- Trial name
- NCT06550830
- Testing
- Sinovac PCV24 formulation 1, Sinovac PCV24 formulation 2, Prevenar13®
- Where
- China
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Infections, Rotavirus
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
This Post Marketing Surveillance (PMS) will collect reactogenicity and safety data on the use of human rotavirus vaccine in healthy infants aged from 6 weeks (first dose) to not more than 24 weeks (second dose).
- Trial name
- NCT00779779
- Testing
- Rotarix™
- Where
- Sri Lanka
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Obesity
Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza
The aim of the study is to evaluate simultaneously the immunological and clinical efficacy and tolerability of an influenza vaccine, inactivated, quadrivalent, with cleaved virus, in patients at risk for severe and complicated…
- Conditions
- Influenza, Obesity, Pregnancy; Infection, Elderly Infection
- Trial name
- NCT06286488
- Testing
- Vaxigrip
- Where
- Poland
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.
- Trial name
- NCT02091908
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 6 sites in Germany
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines
This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control…
- Trial name
- NCT00644059
- Testing
- Adjuvanted trivalent inactivated subunit influenza vaccine, Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine, Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine
- Where
- 101 sites in Finland, Germany and 1 more
- Volunteers
- 4,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly
Since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profile of adjuvanted influenza vaccine need to be re-evaluated after…
- Trial name
- NCT00386113
- Testing
- Fluarix and adjuvanted influenza vaccine
- Where
- Belgium
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population
The purpose of this study is to determine whether the 2010/2011 Formulation Enzira vaccine is safe and elicits an immune response to seasonal influenza in healthy adults.
- Trial name
- NCT01113580
- Testing
- CSL's 2010/2011 Formulation of Enzira® Vaccine
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly
Prospective cohort study to evaluate safety and immunogenicity of the fragmented, inactivated trivalent Influenza vaccine produced at Butantan Institute in healthy adults and elderly.
- Trial name
- NCT02313740
- Testing
- Butantan Fragmented Inactivated Trivalent Influenza Vaccine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Encephalitis, Tick-borne
FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years
The aim of this study is to evaluate the safety of the third vaccination with FSME-IMMUN NEW in all volunteers who received both vaccinations in Baxter study 208 (safety study of FSME IMMUN NEW and ENCEPUR in healthy volunteers…
- Trial name
- NCT00161876
- Testing
- Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)
- Where
- 8 sites in Poland
- Volunteers
- 3,973 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
A Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine
This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the active control, Fluarix Tetra.
- Trial name
- NCT03718468
- Testing
- GC FLU Quadrivalent, Fluarix Tetra
- Where
- 4 sites in Taiwan
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Safety and Immunogenicity of Two 0.25 mL or 0.5 mL Doses of Two Different Influenza Vaccines in Healthy Children Aged 6 to <60 Months
This a multicenter phase II trial will evaluate safety and immunogenicity of two 0.25 mL or 0.5 mL doses of investigational influenza vaccine and active control influenza vaccine in healthy children aged 6 to <60 months.
- Trial name
- NCT00649883
- Testing
- Influenza Trivalent Inactivated vaccines Novartis, Influenza Trivalent Inactivated vaccines
- Where
- 5 sites in Guatemala
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Novartis
Tuberculosis
Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65
The investigators select 500 subjects who meet the standard and are considered as study population I. Do specific gamma-interferon detection before the skin test， then inject intradermally with two dosage ESAT6-CFP10 and…
- Trial name
- IIb-healthy (NCT02389322)
- Testing
- 5μg/ml ESAT6-CFP10, 10μg/ml ESAT6-CFP10, BCG
- Where
- China
- Volunteers
- 1,044 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Varicella (Chickenpox), Varicella Immunisation
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children
This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled.
- Trial name
- NCT07473427
- Testing
- Varicella Vaccine
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
COVID-19
A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy adults ⩾18 years.
- Trial name
- NCT04758273
- Testing
- medium dosage inactivated SARS-CoV-2 vaccine, high dosage inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Beijing Minhai Biotechnology Co., Ltd
Latent Tuberculosis Infection
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients.
- Trial name
- NCT05746611
- Testing
- Recombinant Mycobacterium tuberculosis fusion protein for injection, TB-PPD was injected
- Where
- China
- Volunteers
- 7,500 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Respiratory Syncytial Virus Infections
A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older
The purpose of the current study is to evaluate the immune response of the RSVPreF3 OA investigational vaccine in older adults (OA) at least (>=) 60 years of age (YOA) in China compared to OA in the same age range to be enrolled…
- Trial name
- NCT06551181
- Testing
- RSVPreF3 OA investigational vaccine
- Where
- 40 sites in China, Finland and 5 more
- Volunteers
- 2,620 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older
To evaluate the safety and immunogenicity of COVID-19 mRNA vaccine in people aged 18 years and older, 300 participants will be enrolled and divided into two groups: low- and high-dose groups.
- Trial name
- NCT05373472
- Testing
- COVID-19 mRNA vaccine
- Where
- 3 sites in China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.